Gkaniatsou, Theodora
Papadopoulou, Athina
Paul, Friedemann
Brandt, Alexander Ulrich http://orcid.org/0000-0002-9768-014X
Oertel, Frederike Cosima
Funding for this research was provided by:
Schweizerische Multiple Sklerose Gesellschaft
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P300PB_174480)
Bundesministerium für Bildung und Forschung
Arthur und Aenne Feindt Stiftung
EU FP7 Framework Program
Guthy-Jackson Charitable Foundation
National Multiple Sclerosis of the USA
Article History
Received: 16 March 2019
Accepted: 17 June 2019
First Online: 1 July 2019
Compliance with ethical standards
:
: The authors report no potential conflict of interest regarding this letter. TG has nothing to disclosure. AP has received speaker-fee from Sanofi-Genzyme and travel support from Bayer AG, Teva, Hoffmann-La Roche and ECTRIMS. Her research was supported by the University of Basel, the Swiss Multiple Sclerosis Society and the “Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung sowie der medizinischen Bildauswertung”. The current research work was supported by the Swiss National Science Foundation (Project number: P300PB_174480). FP serves on the scientific advisory board for Novartis; received speaker honoraria and travel funding from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is an academic editor for PLoS ONE; is an associate editor for Neurology<sup>®</sup> Neuroimmunology & Neuroinflammation; consulted for SanofiGenzyme, Biogen Idec, MedImmune, Shire, and Alexion; and received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Arthur Arnstein Founda-tion Berlin, Guthy Jackson Charitable Foundation, and National Multiple Sclerosis of the USA. AUB is cofounder and shareholder of technology startups Motognosis and Nocturne. He is named as inventor on several patent applications describing MS serum biomarkers, perceptive visual computing and retinal image analysis. FCO was employed by Nocturne, unrelated to this project.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All patients gave written informed consent. This article does not contain any studies with animals performed by any of the authors.